Gauranga Mahalwar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gauranga Mahalwar has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Aman Goyal
Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
4 shared publications - Humza Saeed
Department of internal medicine Rawalpindi Medical University Rawalpindi Pakistan
3 shared publications - Mohamed Daoud
Bogomolets National Medical University, Kyiv, Ukraine
3 shared publications - Allan L. Klein
Cleveland Clinic
2 shared publications Aman Goyal
Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA
2 shared publicationsAman Mbbs Goyal
From the Department of Internal Medicine, Seth GS Medical College and KEM Hospital, Mumbai, India
2 shared publications
Latest Publications
- Open Access
- 21 April 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (8) , e040272
Assessing the Cost Effectiveness of an Incremental Lipid‐Lowering Therapy Approach After Coronary Artery Bypass Grafting Using Nationwide Data
Background: Lipid‐lowering therapy (LLT) is important for risk reduction for patients after coronary artery bypass grafting. Cost limits the wider use of PCSK9 (proprotein convertase subtilsin/kexin type 9) inhibitors (PCSK9is) and newer drugs. Hence, mathematical modeling was performed on a nationwide cohort of US veterans post coronary artery bypass grafting to understand the need for expensive drugs like PCSK9is and the cost effectiveness of this model was evaluated. Methods: First, Monte Carlo simulations were used to model the stepwise initiation of high‐intensity statins, ezetimibe, and PCSK9i therapy for each patient to lower their low‐density lipoprotein cholesterol levels to recommended targets. Next, a lifetime Markov model was constructed with stroke, myocardial infarction, repeat revascularization, and mortality rates obtained our study cohort of nationwide US veterans post coronary artery bypass grafting. LLT treatment costs and quality adjusted life years were used to determine the cost effectiveness of this stepwise LLT approach versus observed clinical practice from the health care perspective. Probabilistic models were fit and results for cost effectiveness reported using incremental cost‐effectiveness ratio per quality adjusted life year gained over the lifetime. Results: For 27 443 US veterans post‐ coronary artery bypass grafting (mean age 66 years, 10% Black) with a median low‐density lipoprotein cholesterol 129 (interquartile range, 95.2–180) mg/dL, the 42% and 37% reached target LLT by statin intensification only and including ezetimibe, respectively. Only 6% required bempedoic acid or PCSK9is after the preceding steps. Such stepwise LLT reduction projected 0.8 life years gained over the 30‐year period. With a median incremental cost‐effectiveness ratio of percent 15 232 (interquartile range, 13 520–17 769) per quality adjusted life year gained, this stepwise approach reached 100% probability for being cost effective (compared with observed clinical practice) at willingness‐to‐pay thresholds >$20 000. Conclusions: Few patients needed bempedoic acid or PCSK9is when simulating stepwise LLT with high‐intensity statins and ezetimibe. Such an approach was observed as cost effective at very low willingness‐to‐pay thresholds.
- 21 April 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (8) , e040272
Open AccessAssessing the Cost Effectiveness of an Incremental Lipid‐Lowering Therapy Approach After Coronary Artery Bypass Grafting Using Nationwide Data
Background: Lipid‐lowering therapy (LLT) is important for risk reduction for patients after coronary artery bypass grafting. Cost limits the wider use of PCSK9 (proprotein convertase subtilsin/kexin type 9) inhibitors (PCSK9is) and newer drugs. Hence, mathematical modeling was performed on a nationwide cohort of US veterans post coronary artery bypass grafting to understand the need for expensive drugs like PCSK9is and the cost effectiveness of this model was evaluated. Methods: First, Monte Carlo simulations were used to model the stepwise initiation of high‐intensity statins, ezetimibe, and PCSK9i therapy for each patient to lower their low‐density lipoprotein cholesterol levels to recommended targets. Next, a lifetime Markov model was constructed with stroke, myocardial infarction, repeat revascularization, and mortality rates obtained our study cohort of nationwide US veterans post coronary artery bypass grafting. LLT treatment costs and quality adjusted life years were used to determine the cost effectiveness of this stepwise LLT approach versus observed clinical practice from the health care perspective. Probabilistic models were fit and results for cost effectiveness reported using incremental cost‐effectiveness ratio per quality adjusted life year gained over the lifetime. Results: For 27 443 US veterans post‐ coronary artery bypass grafting (mean age 66 years, 10% Black) with a median low‐density lipoprotein cholesterol 129 (interquartile range, 95.2–180) mg/dL, the 42% and 37% reached target LLT by statin intensification only and including ezetimibe, respectively. Only 6% required bempedoic acid or PCSK9is after the preceding steps. Such stepwise LLT reduction projected 0.8 life years gained over the 30‐year period. With a median incremental cost‐effectiveness ratio of percent 15 232 (interquartile range, 13 520–17 769) per quality adjusted life year gained, this stepwise approach reached 100% probability for being cost effective (compared with observed clinical practice) at willingness‐to‐pay thresholds >$20 000. Conclusions: Few patients needed bempedoic acid or PCSK9is when simulating stepwise LLT with high‐intensity statins and ezetimibe. Such an approach was observed as cost effective at very low willingness‐to‐pay thresholds.
- Open Access
- 31 August 2025
- Published by Elsevier in American Heart Journal Plus: Cardiology Research and Practice
- Vol. 59, 100600
Telemedicine for the detection and management of in-hospital and out-of-hospital sudden cardiac arrest: Status quo and quo vadis
- 31 August 2025
- Published by Elsevier in American Heart Journal Plus: Cardiology Research and Practice
- Vol. 59, 100600
Open AccessTelemedicine for the detection and management of in-hospital and out-of-hospital sudden cardiac arrest: Status quo and quo vadis
- Open Access
- 19 May 2025
- Published by IMR Press in The Heart Surgery Forum
- Vol. 28 (5) , E417-E431
Multimodality Cardiac Imaging Evaluation and Guidance of Management for Aortic Regurgitation
Aortic regurgitation (AR) is a valvular heart disease characterized by the pathological backflow of blood from the aorta into the left ventricle during diastole, causing left ventricular pressure and volume overload. This results in dilation and enlargement of the left ventricle, causing left ventricular hypertrophy and, ultimately, left ventricular dysfunction. AR has a wide range of causes, which include congenital, acquired, and genetic diseases. Therefore, AR may present as an acute condition causing hemodynamic compromise or as a chronic condition with a long asymptomatic phase, which could progress to heart failure (HF). The clinical profile and the disease trajectory depend on the age, sex, and the type of underlying AR pathology. Noninvasive cardiac multimodality imaging (cMMI) has been integral in the serial monitoring and management of AR. Meanwhile, transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE) are mainly utilized as the first-line diagnosis and monitoring options for AR. Furthermore, cardiac magnetic resonance imaging (CMR) is useful in assessing regurgitant volume and the degree of myocardial remodeling. Cardiac computed tomography (CT) is another second-line imaging modality used to evaluate anatomy, particularly for surgical planning. These modalities allow a systematic assessment of AR disease severity and therapeutic decision-making. Surgical aortic valve replacement (SAVR) is the recommended modality for treating severe symptomatic AR. Meanwhile, transcatheter aortic valve replacement (TAVR) may be a potential interventional option for patients at elevated surgical risk; however, the evidence remains limited to patients with mixed aortic valvular disease. Therefore, new research is currently being performed in artificial intelligence and four-dimensional imaging to optimize the diagnostic accuracy of imaging techniques and identify patients who would benefit from early intervention, thus improving outcomes. The primary objective of this review is to explore the different indications, advantages, and disadvantages of cMMI in the diagnosis, follow-up, and treatment of severe AR, highlighting how cMMI can be utilized in optimizing clinical decision-making and patient outcomes.
- 19 May 2025
- Published by IMR Press in The Heart Surgery Forum
- Vol. 28 (5) , E417-E431
Open AccessMultimodality Cardiac Imaging Evaluation and Guidance of Management for Aortic Regurgitation
Aortic regurgitation (AR) is a valvular heart disease characterized by the pathological backflow of blood from the aorta into the left ventricle during diastole, causing left ventricular pressure and volume overload. This results in dilation and enlargement of the left ventricle, causing left ventricular hypertrophy and, ultimately, left ventricular dysfunction. AR has a wide range of causes, which include congenital, acquired, and genetic diseases. Therefore, AR may present as an acute condition causing hemodynamic compromise or as a chronic condition with a long asymptomatic phase, which could progress to heart failure (HF). The clinical profile and the disease trajectory depend on the age, sex, and the type of underlying AR pathology. Noninvasive cardiac multimodality imaging (cMMI) has been integral in the serial monitoring and management of AR. Meanwhile, transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE) are mainly utilized as the first-line diagnosis and monitoring options for AR. Furthermore, cardiac magnetic resonance imaging (CMR) is useful in assessing regurgitant volume and the degree of myocardial remodeling. Cardiac computed tomography (CT) is another second-line imaging modality used to evaluate anatomy, particularly for surgical planning. These modalities allow a systematic assessment of AR disease severity and therapeutic decision-making. Surgical aortic valve replacement (SAVR) is the recommended modality for treating severe symptomatic AR. Meanwhile, transcatheter aortic valve replacement (TAVR) may be a potential interventional option for patients at elevated surgical risk; however, the evidence remains limited to patients with mixed aortic valvular disease. Therefore, new research is currently being performed in artificial intelligence and four-dimensional imaging to optimize the diagnostic accuracy of imaging techniques and identify patients who would benefit from early intervention, thus improving outcomes. The primary objective of this review is to explore the different indications, advantages, and disadvantages of cMMI in the diagnosis, follow-up, and treatment of severe AR, highlighting how cMMI can be utilized in optimizing clinical decision-making and patient outcomes.
- Open Access
- 30 September 2024
- Published by Elsevier in IJC Heart & Vasculature
- Vol. 55, 101519
Is there an obesity paradox in cardiovascular outcomes for patients undergoing Transcatheter Edge-to-Edge Repair? A pilot meta-analysis
- 30 September 2024
- Published by Elsevier in IJC Heart & Vasculature
- Vol. 55, 101519
Open AccessIs there an obesity paradox in cardiovascular outcomes for patients undergoing Transcatheter Edge-to-Edge Repair? A pilot meta-analysis
- Open Access
- 8 August 2024
- Published by Elsevier in Current Problems in Cardiology
- Vol. 49 (12) , 102790
Systematic review and meta-analysis comparing complete versus incomplete or culprit-only revascularization by percutaneous coronary intervention in elderly patients with acute coronary syndrome
- 8 August 2024
- Published by Elsevier in Current Problems in Cardiology
- Vol. 49 (12) , 102790
Open AccessSystematic review and meta-analysis comparing complete versus incomplete or culprit-only revascularization by percutaneous coronary intervention in elderly patients with acute coronary syndrome
- Open Access
- 6 August 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (15) , e034298
Outcomes and Predictors of Stroke After Transcatheter Aortic Valve Replacement in the Cerebral Protection Device Era
Background: Studies have shown inconclusive results on the effectiveness of cerebral protection devices (CPDs) with transcatheter aortic valve replacement. We aimed to analyze the national statistics on stroke and other outcomes with CPD use. Methods and Results: The Nationwide Readmissions Database (2017–2020) was queried to obtain data on patients undergoing transcatheter aortic valve replacement. Outcomes were compared between patients with a CPD and patients without a CPD. Of 271 804 patients undergoing transcatheter aortic valve replacement, CPD was used in 7.3% of patients. In a multivariable logistic regression analysis, CPD use was not associated with lower overall stroke rates (1.6% versus 1.9% without CPD; odds ratio, 0.95 [95% CI, 0.84–1.07]; P =0.364), but it was significantly associated with lower major stroke rates (1.2% versus 1.5% without CPD; odds ratio, 0.85 [95% CI, 0.74–0.98]; P =0.02). Patients with a CPD also had a shorter length of stay, higher routine discharges to home/self‐care (74.9% versus 70.6%), and lower mortality rates (0.7% versus 1.3%). The 30‐day (9.6% versus 11.7%) and 180‐day (24.6% versus 28.2%) readmission rates were significantly lower in the CPD cohort. Among patients who developed stroke, patients with a CPD had more frequent routine discharges. Prior valve surgery was associated with the highest risk of overall and major stroke. Conclusions: CPD use during transcatheter aortic valve replacement was not independently associated with a lower risk of overall stroke but was associated with a lower risk of major stroke in a multivariable model. Data from future randomized trials that may offset any potential confounders in our study are required to help identify patients who would benefit from the use of these devices.
- 6 August 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (15) , e034298
Open AccessOutcomes and Predictors of Stroke After Transcatheter Aortic Valve Replacement in the Cerebral Protection Device Era
Background: Studies have shown inconclusive results on the effectiveness of cerebral protection devices (CPDs) with transcatheter aortic valve replacement. We aimed to analyze the national statistics on stroke and other outcomes with CPD use. Methods and Results: The Nationwide Readmissions Database (2017–2020) was queried to obtain data on patients undergoing transcatheter aortic valve replacement. Outcomes were compared between patients with a CPD and patients without a CPD. Of 271 804 patients undergoing transcatheter aortic valve replacement, CPD was used in 7.3% of patients. In a multivariable logistic regression analysis, CPD use was not associated with lower overall stroke rates (1.6% versus 1.9% without CPD; odds ratio, 0.95 [95% CI, 0.84–1.07]; P =0.364), but it was significantly associated with lower major stroke rates (1.2% versus 1.5% without CPD; odds ratio, 0.85 [95% CI, 0.74–0.98]; P =0.02). Patients with a CPD also had a shorter length of stay, higher routine discharges to home/self‐care (74.9% versus 70.6%), and lower mortality rates (0.7% versus 1.3%). The 30‐day (9.6% versus 11.7%) and 180‐day (24.6% versus 28.2%) readmission rates were significantly lower in the CPD cohort. Among patients who developed stroke, patients with a CPD had more frequent routine discharges. Prior valve surgery was associated with the highest risk of overall and major stroke. Conclusions: CPD use during transcatheter aortic valve replacement was not independently associated with a lower risk of overall stroke but was associated with a lower risk of major stroke in a multivariable model. Data from future randomized trials that may offset any potential confounders in our study are required to help identify patients who would benefit from the use of these devices.
- Open Access
- 25 July 2024
- Published by Elsevier in IJC Heart & Vasculature
- Vol. 53, 101456
Association between inflammatory bowel disease and atrial fibrillation: A systematic review and meta-analysis
- 25 July 2024
- Published by Elsevier in IJC Heart & Vasculature
- Vol. 53, 101456
Open AccessAssociation between inflammatory bowel disease and atrial fibrillation: A systematic review and meta-analysis
- Open Access
Trends, Gender, and Racial Disparities in Patients with Mortality Due to Paroxysmal Tachycardia: A Nationwide Analysis from 1999-2020
Background Paroxysmal tachycardia encompasses various heart rhythm disorders that cause rapid heart rates. Its episodic occurrence makes it difficult to identify and measure its prevalence and trends in the population. Additionally, there is limited data on disparities and trends in mortality due to paroxysmal tachycardia, which is essential for assessing current medical approaches and identifying at-risk populations. Methods Our study examined death certificates from 1999 to 2020 using the CDC WONDER Database to identify deaths caused by paroxysmal tachycardia in individuals aged 25 and older, using the ICD-10 code I47. Age-adjusted mortality rates (AAMRs) and annual percent changes (APC) were calculated by year, gender, age group, race/ethnicity, geographic location, and urbanization status. Results Between 1999 and 2020, 155,320 deaths were reported in patients with paroxysmal tachycardia. Overall, AAMR decreased from 4.8 to 3.7 per 100,000 population between 1999 and 2020, despite showing a significant increase from 2014 to 2020 (APC: 4.33; 95% CI: 3.53 to 5.56). Men had consistently higher AAMRs than women (4.7 vs. 2.2). Furthermore, we found that AAMRs were highest among Non-Hispanic (NH) Black or African Americans and lowest in NH Asian or Pacific Islanders (4 vs. 1.9). Nonmetropolitan areas had higher AAMRs than metropolitan areas (3.6 vs. 3.2). Conclusions Our analysis showed a significant decrease in mortality from paroxysmal tachycardia since 1999, although there has been a slight increase in recent years. However, disparities remain, with higher AAMRs among men, NH Black or African Americans, and residents of non-metropolitan areas. These findings call for immediate public health actions to curb the rising trends and reduce potential disparities. Clinical Perspectives What is New? In this analysis of population-level US mortality data from 1999 to 2020, we observed an overall decrease in mortality due to Paroxysmal Tachycardia, despite a significant upward trend from 2014 to 2020. Older adults had higher age-adjusted mortality rates than young and middle-aged adults, and men had higher mortality rates than women. Non-Hispanic Black or African Americans had the highest mortality rates among racial groups, and those in non-metropolitan areas had higher rates than those in metropolitan areas. What Are the Clinical Implications? By addressing the effects of the pandemic and racial disparities, healthcare providers and policymakers can develop effective strategies to address this concerning trend. Education should not only identify risk factors but also work to change the socio-cultural conditions that cause these risks.
Open AccessTrends, Gender, and Racial Disparities in Patients with Mortality Due to Paroxysmal Tachycardia: A Nationwide Analysis from 1999-2020
Background Paroxysmal tachycardia encompasses various heart rhythm disorders that cause rapid heart rates. Its episodic occurrence makes it difficult to identify and measure its prevalence and trends in the population. Additionally, there is limited data on disparities and trends in mortality due to paroxysmal tachycardia, which is essential for assessing current medical approaches and identifying at-risk populations. Methods Our study examined death certificates from 1999 to 2020 using the CDC WONDER Database to identify deaths caused by paroxysmal tachycardia in individuals aged 25 and older, using the ICD-10 code I47. Age-adjusted mortality rates (AAMRs) and annual percent changes (APC) were calculated by year, gender, age group, race/ethnicity, geographic location, and urbanization status. Results Between 1999 and 2020, 155,320 deaths were reported in patients with paroxysmal tachycardia. Overall, AAMR decreased from 4.8 to 3.7 per 100,000 population between 1999 and 2020, despite showing a significant increase from 2014 to 2020 (APC: 4.33; 95% CI: 3.53 to 5.56). Men had consistently higher AAMRs than women (4.7 vs. 2.2). Furthermore, we found that AAMRs were highest among Non-Hispanic (NH) Black or African Americans and lowest in NH Asian or Pacific Islanders (4 vs. 1.9). Nonmetropolitan areas had higher AAMRs than metropolitan areas (3.6 vs. 3.2). Conclusions Our analysis showed a significant decrease in mortality from paroxysmal tachycardia since 1999, although there has been a slight increase in recent years. However, disparities remain, with higher AAMRs among men, NH Black or African Americans, and residents of non-metropolitan areas. These findings call for immediate public health actions to curb the rising trends and reduce potential disparities. Clinical Perspectives What is New? In this analysis of population-level US mortality data from 1999 to 2020, we observed an overall decrease in mortality due to Paroxysmal Tachycardia, despite a significant upward trend from 2014 to 2020. Older adults had higher age-adjusted mortality rates than young and middle-aged adults, and men had higher mortality rates than women. Non-Hispanic Black or African Americans had the highest mortality rates among racial groups, and those in non-metropolitan areas had higher rates than those in metropolitan areas. What Are the Clinical Implications? By addressing the effects of the pandemic and racial disparities, healthcare providers and policymakers can develop effective strategies to address this concerning trend. Education should not only identify risk factors but also work to change the socio-cultural conditions that cause these risks.
- 11 July 2024
- Published by Wolters Kluwer Health in Cardiology in Review
Direct Oral Anticoagulants Exhibit Lower Risks of Mortality and Bleeding Compared to Vitamin K Antagonists in Atrial Fibrillation Patients on Chronic Hemodialysis: A Systematic Review and Meta-Analysis
This meta-analysis aimed to assess the outcomes of patients with atrial fibrillation undergoing chronic hemodialysis, comparing the effectiveness of direct oral anticoagulants (DOACs) and vitamin K antagonists. A systematic search was conducted across various databases including PubMed, Embase, and Google Scholar. Efficacy outcomes focused on the risk of stroke and mortality, whereas safety outcomes assessed the risk of bleeding. Review Manager generated forest plots for data synthesis. Statistical significance was set at P < 0.05, and random-effects models were used. Subgroup analysis identified the sources of heterogeneity. Nine studies met the inclusion criteria for the final analysis. The risk of all-cause stroke [risk ratio (RR): 0.64; 95% confidence interval (CI): 0.51–0.81; P = 0.0001; I 2 = 0%], ischemic stroke (RR: 0.53; 95% CI: 0.29–0.96; P = 0.04; I 2 = 0%), all-cause mortality (RR: 0.73; 95% CI: 0.60–0.88; P = 0.001; I 2 = 71%), major bleeding (RR: 0.63; 95% CI: 0.52–0.76; P < 0.00001; I 2 = 44%), gastrointestinal bleeding (RR: 0.67; 95% CI: 0.53-0.85; P = 0.0009; I 2 = 36%), intracranial hemorrhage (RR: 0.57; 95% CI: 0.38–0.84; P = 0.004; I 2 = 0%) were lower in the DOAC group compared with the vitamin K antagonist group. The risk of cardiovascular-related death (RR: 1.34; 95% CI: 0.69–2.60; P = 0.39; I 2 = 0%), clinically relevant nonmajor bleeding (RR: 0.90; 95% CI: 0.75–1.08; P = 0.26; I 2 = 28%), and hemorrhagic stroke (RR: 0.36; 95% CI: 0.06–2.24; P = 0.28; I 2 = 10%) showed no significant differences. In conclusion, the risks of all-cause stroke, ischemic stroke, all-cause mortality, major bleeding, gastrointestinal bleeding, and intracranial hemorrhage in patients with atrial fibrillation undergoing chronic hemodialysis were lower in the DOAC group.
- 11 July 2024
- Published by Wolters Kluwer Health in Cardiology in Review
Direct Oral Anticoagulants Exhibit Lower Risks of Mortality and Bleeding Compared to Vitamin K Antagonists in Atrial Fibrillation Patients on Chronic Hemodialysis: A Systematic Review and Meta-Analysis
This meta-analysis aimed to assess the outcomes of patients with atrial fibrillation undergoing chronic hemodialysis, comparing the effectiveness of direct oral anticoagulants (DOACs) and vitamin K antagonists. A systematic search was conducted across various databases including PubMed, Embase, and Google Scholar. Efficacy outcomes focused on the risk of stroke and mortality, whereas safety outcomes assessed the risk of bleeding. Review Manager generated forest plots for data synthesis. Statistical significance was set at P < 0.05, and random-effects models were used. Subgroup analysis identified the sources of heterogeneity. Nine studies met the inclusion criteria for the final analysis. The risk of all-cause stroke [risk ratio (RR): 0.64; 95% confidence interval (CI): 0.51–0.81; P = 0.0001; I 2 = 0%], ischemic stroke (RR: 0.53; 95% CI: 0.29–0.96; P = 0.04; I 2 = 0%), all-cause mortality (RR: 0.73; 95% CI: 0.60–0.88; P = 0.001; I 2 = 71%), major bleeding (RR: 0.63; 95% CI: 0.52–0.76; P < 0.00001; I 2 = 44%), gastrointestinal bleeding (RR: 0.67; 95% CI: 0.53-0.85; P = 0.0009; I 2 = 36%), intracranial hemorrhage (RR: 0.57; 95% CI: 0.38–0.84; P = 0.004; I 2 = 0%) were lower in the DOAC group compared with the vitamin K antagonist group. The risk of cardiovascular-related death (RR: 1.34; 95% CI: 0.69–2.60; P = 0.39; I 2 = 0%), clinically relevant nonmajor bleeding (RR: 0.90; 95% CI: 0.75–1.08; P = 0.26; I 2 = 28%), and hemorrhagic stroke (RR: 0.36; 95% CI: 0.06–2.24; P = 0.28; I 2 = 10%) showed no significant differences. In conclusion, the risks of all-cause stroke, ischemic stroke, all-cause mortality, major bleeding, gastrointestinal bleeding, and intracranial hemorrhage in patients with atrial fibrillation undergoing chronic hemodialysis were lower in the DOAC group.
- 6 July 2024
- Published by Wolters Kluwer Health in Cardiology in Review
Transcatheter Edge-to-Edge Repair in Valvular Heart Disease: A Comprehensive Exploration of Equipment, Efficacy, Gender, Racial, and Socioeconomic Disparities, and Future Prospects
The 2 primary components of valvular heart disease are mitral regurgitation (MR) and tricuspid regurgitation (TR). Transcatheter edge-to-edge repair (TEER) is an advanced, minimally invasive procedure that has recently displayed encouraging outcomes in the treatment of these pathologies. TEER offers a nonsurgical alternative for individuals diagnosed with conditions deemed to be high-risk surgical candidates. Currently, the TEER procedure employs devices such as MitraCLIP and TriCLIP, as well as innovative PASCAL (transcatheter valve repair system used for mitral and tricuspid valve repair) and FORMA (repair system used for tricuspid valve repair) repair systems. In the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) trial enrolling 614 patients to test the efficacy of TEER in MR, a significant reduction in hospitalization due to heart failure was observed at 24 months in the MitraClip + guideline-directed medical therapy (GDMT) group (35.8%) than in the GDMT-alone group (67.9%), HR, 0.53; P < 0.001, lower rate of all-cause mortality at 29.1% compared with 46.1% (P < 0.001), lower risk of cerebrovascular events (P = 0.001), and lower mortality due to cardiovascular events (P < 0.001). In another trial, patients with moderate TR or greater than New York Heart Association Class II or higher underwent TEER using the TriClip for the management of TR. The outcomes were encouraging, with 86% of patients showing a reduction in TR severity of at least one grade. As the technology and research surrounding TEER continue to progress, a more extensive range of patients are expected to qualify for TEER procedures. Our comprehensive review sought to extensively explore the background, equipment used, effectiveness of MR and TR, potential side effects, future prospects, and ongoing trials associated with TEER. We further discuss the existing gender, racial, and socioeconomic disparities in the realm of TEER.-
- 6 July 2024
- Published by Wolters Kluwer Health in Cardiology in Review
Transcatheter Edge-to-Edge Repair in Valvular Heart Disease: A Comprehensive Exploration of Equipment, Efficacy, Gender, Racial, and Socioeconomic Disparities, and Future Prospects
The 2 primary components of valvular heart disease are mitral regurgitation (MR) and tricuspid regurgitation (TR). Transcatheter edge-to-edge repair (TEER) is an advanced, minimally invasive procedure that has recently displayed encouraging outcomes in the treatment of these pathologies. TEER offers a nonsurgical alternative for individuals diagnosed with conditions deemed to be high-risk surgical candidates. Currently, the TEER procedure employs devices such as MitraCLIP and TriCLIP, as well as innovative PASCAL (transcatheter valve repair system used for mitral and tricuspid valve repair) and FORMA (repair system used for tricuspid valve repair) repair systems. In the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) trial enrolling 614 patients to test the efficacy of TEER in MR, a significant reduction in hospitalization due to heart failure was observed at 24 months in the MitraClip + guideline-directed medical therapy (GDMT) group (35.8%) than in the GDMT-alone group (67.9%), HR, 0.53; P < 0.001, lower rate of all-cause mortality at 29.1% compared with 46.1% (P < 0.001), lower risk of cerebrovascular events (P = 0.001), and lower mortality due to cardiovascular events (P < 0.001). In another trial, patients with moderate TR or greater than New York Heart Association Class II or higher underwent TEER using the TriClip for the management of TR. The outcomes were encouraging, with 86% of patients showing a reduction in TR severity of at least one grade. As the technology and research surrounding TEER continue to progress, a more extensive range of patients are expected to qualify for TEER procedures. Our comprehensive review sought to extensively explore the background, equipment used, effectiveness of MR and TR, potential side effects, future prospects, and ongoing trials associated with TEER. We further discuss the existing gender, racial, and socioeconomic disparities in the realm of TEER.-